Maxim Group Assumes Momenta Pharmaceuticals (MNTA) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Momenta Phama's (MNTA) Necuparanib Receives Orphan Drug Designation from FDA
June 5, 2014 8:05 AM EDTMomenta Phama (NASDAQ: MNTA) announced that its novel oncology candidate, necuparanib (formerly M402), has received Orphan Drug Designation from the FDA for the treatment of pancreatic cancer.
"We are pleased to receive Orphan Drug Designation for... More
